NIH R01 · 2024
PROJECT SUMMARY The Plasmodium falciparum circumsporozoite protein (CSP) is an attractive malaria vaccine candidate because anti-CSP antibodies can block liver invasion and potentially provide sterilizing immunity against the parasite. However, current vaccines that target CSP, including RTS,S, the most advanced malaria vaccine, elicit suboptimal protective immunity that wanes dramatically over time. In this proposal, our goal is to engineer new and more effective vaccines targeting CSP. We will take advantage of the recent identification of potently protective monoclonal antibodies that target epitopes within novel sites of vulnerability in CSP. We will specifically target these epitopes…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.